Skip to main content
Hauptrubriken
Zeitschriften Fortbildung Hebammen Bücher Kongresse & Live-Webinare
Social Media - Folgen Sie uns!
Instagram Facebook LinkedIn Instagram Hebammen
Service
Jobbörse Kundenservice Info & Hilfe
Fokus-Themen
Chronisch-entzündliche Darmerkrankung COVID-19-Update Diabetes Hautpflege Klima & Gesundheit Hygiene Intensivpflege Kardiologische Pflege Mobilisation Nachhaltigkeit Nierenerkrankungen Obstipation Onkologische Pflege Palliativpflege Schmerz Sucht in der Pflege Vielfalt, Gleichberechtigung und Inklusion Wundversorgung
Erweiterte Suche
Anmelden
nach oben
Zeitschrift für Gerontologie und Geriatrie
Erschienen in:

01.02.2012 | Beiträge zum Themenschwerpunkt

Proteinglykierung als pathophysiologischer Mechanismus bei Diabetes

verfasst von: Prof. Dr. A. Simm, A. Navarrete-Santos, B. Hofmann, H. Bushnaq, N. Nass

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Inzidenz für Diabetes ist in den letzten Jahren stark gestiegen. Diabetes ist durch erhöhte Zuckerkonzentrationen im Blut gekennzeichnet. Infolge dieser Dysregulation entstehen endogen vermehrt zuckerinduzierte Modifikationen von Proteinen, sog. fortgeschrittene Glykierungsendprodukte („advanced glycation end products“, AGEs), durch chemische, nichtenzymatische Reaktionen. Diese sollen ursächlich zur Pathophysiologie von diabetesassoziierten Folgeerkrankungen beitragen. Die Akkumulation von AGEs im Gewebe kann als Prädiktor für die Prognose von Patienten mit Diabetes dienen. Die gesundheitlichen Effekte der über die Nahrung aufgenommenen AGEs sind dagegen immer noch unklar.
Vorheriger Artikel Oxidativer Stress im Endothel und bei Diabetes Typ 2
Nächster Artikel RAGE influences obesity in mice
Literatur
1.
Centers for Disease Control and Prevention (2007) National surveillance data. CDC, Atlanta/GA. http://​apps.​nccd.​cdc.​gov/​DDTSTRS/​NationalSurvData​.​aspx.​ Zugegriffen: 23.09.2011
2.
Olshansky SJ et al (2005) A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352(11):1138–1145PubMedCrossRef
3.
Nass N, Simm A (2009) Advanced glycation end products (AGEs) in diabetes. Abhandlungen Sächsische Akademie der Wissenschaften zu Leipzig 65(3):63–75
4.
Maillard LC (1912) Action des acides amines sur les sucres: formation des melanoidines par voie methodique. CR Acad Sci Ser 154:66–68
5.
Nass N et al (2007) Advanced glycation end products, diabetes and ageing. Z Gerontol Geriatr 40(5):349–356PubMedCrossRef
6.
Bunn HF, Higgins PJ (1981) Reaction of monosaccharides with proteins: possible evolutionary significance. Science 213(4504):222–224PubMedCrossRef
7.
Sebekova K et al (2001) Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet. Eur J Nutr 40(6):275–281PubMedCrossRef
8.
Sato T et al (2006) TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 6(3):351–358PubMedCrossRef
9.
Mericq V et al (2010) Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care 33(10):2232–2237PubMedCrossRef
10.
Cai W et al (2007) Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 170(6):1893–1902PubMedCrossRef
11.
Sebekova K, Somoza V (2007) Dietary advanced glycation endproducts (AGEs) and their health effects – PRO. Mol Nutr Food Res 51(9):1079–1084PubMedCrossRef
12.
Stolzing A et al (2006) Degradation of glycated bovine serum albumin in microglial cells. Free Radic Biol Med 40(6):1017–1027PubMedCrossRef
13.
Nass N et al (2010) Glycation of PDGF results in decreased biological activity. Int J Biochem Cell Biol 42(5):749–754PubMedCrossRef
14.
O’Harte FP et al (1996) Identification of the site of glycation of human insulin. Peptides 17(8):1323–1330CrossRef
15.
Bartling B et al (2009) Age-associated changes of extracellular matrix collagen impair lung cancer cell migration. Faseb J 23(5):1510–1520PubMedCrossRef
16.
Konova E et al (2004) Age-related changes in the glycation of human aortic elastin. Exp Gerontol 39(2):249–254PubMedCrossRef
17.
Hernebring M et al (2006) Elimination of damaged proteins during differentiation of embryonic stem cells. Proc Natl Acad Sci USA 103(20):7700–7705PubMedCrossRef
18.
Vlassara H (2001) The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 17(6):436–4343PubMedCrossRef
19.
Schmidt AM et al (2000) RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 26(5):485–493PubMedCrossRef
20.
Sourris KC, Forbes JM (2009) Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy – are these receptors valid therapeutic targets. Curr Drug Targets 10(1):42–50PubMedCrossRef
21.
Bierhaus A, Humpert PM, Nawroth PP (2006) Linking stress to inflammation. Anesthesiol Clin 24(2):325–340PubMedCrossRef
22.
Dronavalli S, Duka I, Bakris GL (2008) The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4(8):444–452PubMedCrossRef
23.
Vlassara H (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91(24):11704–11708PubMedCrossRef
24.
YamamotoY et al (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108(2):261–268
25.
Iacobini C et al (2005) Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice. Am J Physiol Renal Physiol 289(3):611–621CrossRef
26.
Myint KM et al (2006) RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 55(9):2510–2522PubMedCrossRef
27.
Miyata T et al (1998) Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 53(2):416–422PubMedCrossRef
28.
Forbes JM et al (2001) Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44(1):108–114PubMedCrossRef
29.
Bhattacharyya J et al (2007) Effect of a single AGE modification on the structure and chaperone activity of human alphaB-crystallin. Biochemistry 46(50):14682–14692PubMedCrossRef
30.
Fong DS et al (2004) Retinopathy in diabetes. Diabetes Care 27 (Suppl 1):84–87CrossRef
31.
Khan ZA, Chakrabarti S (2007) Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp Diabetes Res 2007:31867PubMedCrossRef
32.
Madsen-Bouterse SA, Kowluru RA (2008) Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord
33.
Barile GR, Schmidt AM (2007) RAGE and its ligands in retinal disease. Curr Mol Med 7(8):758–765PubMedCrossRef
34.
Stitt AW et al (1997) Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 150(2):523–531PubMed
35.
Amano S et al (2001) Advanced glycation end products in human optic nerve head. Br J Ophthalmol 85(1):52–55PubMedCrossRef
36.
Stitt AW et al (2004) Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia 47(10):1735–1746PubMedCrossRef
37.
Chen AS et al (2004) Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. Horm Metab Res 36(3):183–187PubMedCrossRef
38.
Ino-ue M, Ohgiya N, Yamamoto M (1998) Effect of aminoguanidine on optic nerve involvement in experimental diabetic rats. Brain Res 800(2):319–322PubMedCrossRef
39.
Mazzone T, Chait A, Plutzky J (2008) Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371(9626):1800–1809PubMedCrossRef
40.
Brownlee M et al (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232(4758):1629–1632PubMedCrossRef
41.
Vlassara H et al (1995) Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1(4):447–456PubMed
42.
Endemann G et al (1993) CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268(16):11811–11816PubMed
43.
Ohgami N et al (2003) Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism. J Atheroscler Thromb 10(1):1–6PubMedCrossRef
44.
Park L et al (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4(9):1025–1031PubMedCrossRef
45.
Koyama Y et al (2008) Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 14(2):133–139PubMedCrossRef
46.
Koyama H et al (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25(12):2587–2593PubMedCrossRef
47.
Koyama H et al (2007) Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27(1):147–153PubMedCrossRef
48.
Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18(49):6853–6866PubMedCrossRef
49.
Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115(5):1111–1119PubMed
50.
Bartling B et al (2011) Effect of diabetes mellitus on the outcome of patients with resected non-small cell lung carcinoma. Gerontology 57(6):497–501PubMedCrossRef
51.
Bartling B et al (2011) Prognostic potential and tumor growth-inhibiting effect of plasma advanced glycation end products in non-small cell lung carcinoma. Mol Med 17(9–10):980–989
52.
Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99(3):457–468PubMedCrossRef
53.
Sell DR, Kleinman NR, Monnier VM (2000) Longitudinal determination of skin collagen glycation and glycoxidation rates predicts early death in C57BL/6NNIA mice. Faseb J 14(1):145–156PubMed
54.
Aso Y et al (2000) Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 37(2):87–92PubMedCrossRef
55.
Haus JM et al (2007) Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol 103(6):2068–2076PubMedCrossRef
56.
Meerwaldt R et al (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30(1):107–112PubMedCrossRef
Metadaten
Titel
Proteinglykierung als pathophysiologischer Mechanismus bei Diabetes
verfasst von
Prof. Dr. A. Simm
A. Navarrete-Santos
B. Hofmann
H. Bushnaq
N. Nass
Publikationsdatum
01.02.2012
Verlag
Springer-Verlag
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 2/2012
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-011-0282-2

Weitere Artikel der Ausgabe 2/2012

Mitteilungen der ÖGGG Heft 2/2012

  • Mitteilungen der ÖGGG

Ergebnisse und Prädiktoren der geriatrischen Frührehabilitation im Akutkrankenhaus

  • Originalarbeit

Oxidativer Stress im Endothel und bei Diabetes Typ 2

  • Beiträge zum Themenschwerpunkt

Mitteilungen der DGG Heft 2/2012

  • Mitteilungen der DGG

Mitteilungen der DGGG, Heft 2/2012

  • Mitteilungen der DGGG

RAGE influences obesity in mice

  • Beiträge zum Themenschwerpunkt